selected publications
-
academic article
-
Acute decompensation boosts hepatic collagen type III deposition and deteriorates experimental and human cirrhosis.
Hepatology Communications.
2.
2018
Myocardial extracellular volume quantified by magnetic resonance is increased in cirrhosis and related to poor outcome.
Liver International.
38.
2018
No effect of rifaximin on soluble CD163, mannose receptor or type III and IV neoepitope collagen markers in decompensated cirrhosis: Results from a randomized, placebo controlled trial.
PLoS ONE.
13.
2018
Pronounced Coronary Arteriosclerosis in Cirrhosis: Influence on Cardiac Function and Survival?.
Digestive Diseases and Sciences.
63.
2018
Rifaximin has minor effects on bacterial composition, inflammation, and bacterial translocation in cirrhosis: A randomized trial.
Journal of Gastroenterology and Hepatology.
33.
2018
The pathophysiology of arterial vasodilatation and hyperdynamic circulation in cirrhosis.
Liver International.
38.
2018
Total bile acid levels are associated with left atrial volume and cardiac output in patients with cirrhosis.
European Journal of Gastroenterology & Hepatology.
30.
2018
Transjugular intrahepatic portosystemic shunt: impact on systemic hemodynamics and renal and cardiac function in patients with cirrhosis..
AJP Gastrointestinal and Liver Physiology.
314.
2018
Validation of non‐invasive haemodynamic methods in patients with liver disease: the Finometer and the Task Force Monitor.
Clinical Physiology and Functional Imaging.
38.
2018
Aquaporin‐2 excretion in hospitalized patients with cirrhosis: Relation to development of renal insufficiency and mortality.
Journal of Gastroenterology and Hepatology.
32.
2017
Assessment of systolic function in the evaluation of patients with cirrhosis.
Hepatology.
65.
2017
Bile acids and cardiovascular function in cirrhosis.
Liver International.
37.
2017
Cardiac imaging in patients with chronic liver disease.
Clinical Physiology and Functional Imaging.
37.
2017
Cardiovascular Effects of a Transjugular Intrahepatic Portosystemic Shunt in Patients with Cirrhosis.
Current Hepatology Reports.
16.
2017
Effects of transjugular intrahepatic portosystemic shunt (TIPS) on blood volume distribution in patients with cirrhosis.
Digestive and Liver Disease.
49.
2017
Neutrophil gelatinase‐associated lipocalin and cystatin C in cirrhosis and portal hypertension: Relations to organ extraction and dysfunction.
Journal of Gastroenterology and Hepatology.
32.
2017
Rifaximin has no effect on hemodynamics in decompensated cirrhosis: A randomized, double‐blind, placebo‐controlled trial.
Hepatology.
65.
2017
Selective imaging modalities after first pyelonephritis failed to identify significant urological anomalies, despite normal antenatal ultrasounds.
Acta Paediatrica.
106.
2017
The royal free hospital cirrhosis glomerular filtration rate: Validation in a danish cohort.
Hepatology.
66.
2017
The soluble mannose receptor (sMR) is elevated in alcoholic liver disease and associated with disease severity, portal hypertension, and mortality in cirrhosis patients.
PLoS ONE.
12.
2017
The soluble mannose receptor is released from the liver in cirrhotic patients, but is not associated with bacterial translocation.
Liver International.
37.
2017
Toxicity and efficacy of re-irradiation of high-grade glioma in a phase I dose- and volume escalation trial.
Radiotherapy and Oncology.
125.
2017
Advances in the treatment of portal hypertension in cirrhosis.
Expert Review of Gastroenterology & Hepatology.
10.
2016
Assessment of response to beta-blockers by expression of βArr2 and RhoA/ROCK2 in antrum mucosa in cirrhotic patients.
Journal of Hepatology.
64.
2016
Diastolic dysfunction in cirrhosis.
Heart Failure Reviews.
21.
2016
Editorial: measuring inflammatory and fibrotic components of portal hypertension – a non‐invasive hepatic venous pressure gradient? Authors’ reply.
Alimentary Pharmacology & Therapeutics.
44.
2016
Hepatic erythropoietin response in cirrhosis.
Scandinavian Journal of Clinical and Laboratory Investigation.
76.
2016
Hepatic erythropoietin response in cirrhosis. A contemporary review.
Scandinavian Journal of Clinical and Laboratory Investigation.
76.
2016
Hepatorenal syndrome in cirrhosis: diagnostic, pathophysiological, and therapeutic aspects.
Expert Review of Gastroenterology & Hepatology.
10.
2016
Indocyanine green retention test (ICG-r15) as a noninvasive predictor of portal hypertension in patients with different severity of cirrhosis.
European Journal of Gastroenterology & Hepatology.
28.
2016
Plasma ADAMTS-13 protein is not associated with portal hypertension or hemodynamic changes in patients with cirrhosis.
Digestive and Liver Disease.
48.
2016
Prognostic value of 18F-FET PET imaging in re-irradiation of high-grade glioma: Results of a phase I clinical trial.
Radiotherapy and Oncology.
121.
2016
Research update for articles published in EJCI in 2014.
European Journal of Clinical Investigation.
46.
2016
The macrophage activation marker sCD163 combined with markers of the Enhanced Liver Fibrosis (ELF) score predicts clinically significant portal hypertension in patients with cirrhosis.
Alimentary Pharmacology & Therapeutics.
43.
2016
Toward new standards for noninvasive measuring of portal pressure?.
Hepatology.
63.
2016
Acid–base disturbance in patients with cirrhosis.
European Journal of Gastroenterology & Hepatology.
27.
2015
Beta-blockers in cirrhosis and refractory ascites: a retrospective cohort study and review of the literature.
Scandinavian Journal of Gastroenterology.
50.
2015
Cardiovascular complications of NAFLD—they do matter.
Nature Reviews Gastroenterology & Hepatology.
12.
2015
Circulating Elastin Fragments Are Not Affected by Hepatic, Renal and Hemodynamic Changes, But Reflect Survival in Cirrhosis with TIPS.
Digestive Diseases and Sciences.
60.
2015
Cirrhotic Multiorgan Syndrome.
Digestive Diseases and Sciences.
60.
2015
Complications of cirrhosis. A 50 years flashback.
Scandinavian Journal of Gastroenterology.
50.
2015
Early changes in perfusion of glioblastoma during radio- and chemotherapy evaluated by T1-dynamic contrast enhanced magnetic resonance imaging.
Acta Oncologica.
54.
2015
Expression of vasoactive proteins in gastric antral mucosa reflects vascular dysfunction in patients with cirrhosis and portal hypertension.
Liver International.
35.
2015
Immunologic, hemodynamic, and adrenal incompetence in cirrhosis: impact on renal dysfunction.
Hepatology International.
9.
2015
Management of cirrhotic ascites.
Therapeutic Advances in Chronic Disease.
6.
2015
P1337 : Randomized trial with rifaximin in liver cirrhosis. Effects on the haemodynamic and inflammatory state.
Journal of Hepatology.
62.
2015
Predictive value of indocyanine green retention test and indocyanine green clearance in Child‐Pugh class A patients.
Hepatology.
61.
2015
Pro-C5, a marker of true type V collagen formation and fibrillation, correlates with portal hypertension in patients with alcoholic cirrhosis.
Scandinavian Journal of Gastroenterology.
50.
2015
Rifaximin for people with hepatic encephalopathy.
Cochrane Database of Systematic Reviews.
2015
Assessment of diastolic function in the management of patients with cirrhosis.
Hepatology International.
8.
2014
Association of markers of bacterial translocation with immune activation in decompensated cirrhosis.
European Journal of Gastroenterology & Hepatology.
26.
2014
Cardiac Function in Patients with Early Cirrhosis during Maximal Beta-Adrenergic Drive: A Dobutamine Stress Study.
PLoS ONE.
9.
2014
Cardiac and proinflammatory markers predict prognosis in cirrhosis.
Liver International.
34.
2014
Cirrhotic cardiomyopathy: pathogenesis and clinical relevance.
Nature Reviews Gastroenterology & Hepatology.
11.
2014
Combined antiretroviral therapy attenuates hepatic extracellular matrix remodeling in HIV patients assessed by novel protein fingerprint markers.
AIDS.
28.
2014
Diastolic and autonomic dysfunction in early cirrhosis: a dobutamine stress study.
Scandinavian Journal of Gastroenterology.
49.
2014
Effects of carvedilol and propranolol on circulatory regulation and oxygenation in cirrhosis: A randomised study.
Digestive and Liver Disease.
46.
2014
Efficient Identification of miRNAs for Classification of Tumor Origin.
Journal of Molecular Diagnostics.
16.
2014
Kidney injury in cirrhosis: pathophysiological and therapeutic aspects of hepatorenal syndromes.
Liver International.
34.
2014
New vasoactive peptides in cirrhosis: organ extraction and relation to the vasodilatory state.
European Journal of Clinical Investigation.
44.
2014
PRO-C3-Levels in Patients with HIV/HCV-Co-Infection Reflect Fibrosis Stage and Degree of Portal Hypertension.
PLoS ONE.
9.
2014
RT-22MRI AND FET PET FOR RADIOTHERAPY PLANNING IN RECURRENT HIGH-GRADE GLIOMA (HGG) IN A PROSPECTIVE PHASE I TRIAL.
Neuro-Oncology.
16.
2014
Systematic review with meta‐analysis: the effects of rifaximin in hepatic encephalopathy.
Alimentary Pharmacology & Therapeutics.
40.
2014
TIMP-1 in patients with cirrhosis: relation to liver dysfunction, portal hypertension, and hemodynamic changes.
Scandinavian Journal of Gastroenterology.
49.
2014
-
chapter
-
Cardiac Biomarkers in Cirrhosis and Portal Hypertension: Relation to Circulatory and Cardiac Dysfunction.
Springer Nature.
2016
Variceal Rebleeding: Drugs, Endoscopy or Both.
Springer Nature.
2014
-
dataset
-
Table_1_Clinical Characteristics of Gliosarcoma and Outcomes From Standardized Treatment Relative to Conventional Glioblastoma.docx.
frontiers.
2019
Table_2_Clinical Characteristics of Gliosarcoma and Outcomes From Standardized Treatment Relative to Conventional Glioblastoma.docx.
frontiers.
2019
Table_3_Clinical Characteristics of Gliosarcoma and Outcomes From Standardized Treatment Relative to Conventional Glioblastoma.docx.
frontiers.
2019
Table_4_Clinical Characteristics of Gliosarcoma and Outcomes From Standardized Treatment Relative to Conventional Glioblastoma.docx.
frontiers.
2019
Demographic characteristics in the two groups (rifaximin-α and placebo) [24]..
public-library-of-science.
2018
Neoepitope markers of collagen remodeling before and after treatment..
public-library-of-science.
2018
No effect of rifaximin on soluble CD163, mannose receptor or type III and IV neoepitope collagen markers in decompensated cirrhosis: Results from a randomized, placebo controlled trial.
public-library-of-science.
2018
Multiple logistic regression analyses of the relationships between Clinically significant portal hypertension & sMR, CRP, GEC, and MELD-score..
public-library-of-science.
2017
Smr data.dta..
public-library-of-science.
2017
Study entry characteristics of patients with alcoholic hepatitis and patients with stable alcoholic liver cirrhosis and healthy persons (Data are median (interquartile range))..
public-library-of-science.
2017
Biochemical parameters of included patients..
public-library-of-science.
2014
Cardiovascular function in 19 patients with cirrhosis and 7 controls at rest and after pharmacological stress with dobutamine +/− atropine..
public-library-of-science.
2014
Clinical parameters of patients..
public-library-of-science.
2014
Correlations of PRO-C3 with fibrosis, portal hypertension and liver function..
public-library-of-science.
2014
Demographic, clinical, and biochemical characteristics of patients with cirrhosis and controls..
public-library-of-science.
2014
PRO-C3-Levels in Patients with HIV/HCV-Co-Infection Reflect Fibrosis Stage and Degree of Portal Hypertension.
public-library-of-science.
2014
-
hide from search
-
Biochemical and haemodynamic parameters before TIPS insertion and at early invasive TIPS check after a median of fourteen days (n = 49)..
public-library-of-science.
2013
Clinical parameters of the patients (n = 49) at the time of TIPS placement..
public-library-of-science.
2013
Cox regression analysis (forward step-wise likelihood-quotient) using the significant variable from univariate analysis (table 3) to predict survival..
public-library-of-science.
2013
Univariate time-to-event analysis of patients' characteristics (including variables of table 1 and 2)..
public-library-of-science.
2013
99mTc‐labelled human serum albumin cannot replace 125I‐labelled human serum albumin to determine plasma volume in patients with liver disease.
Clinical Physiology and Functional Imaging.
2013
Different injection techniques in the assessment of central haemodynamics in patients with cirrhosis.
Scandinavian Journal of Clinical and Laboratory Investigation.
2013
Interactions of the heart and the liver.
European Heart Journal.
2013
Lactate metabolism in chronic liver disease.
Scandinavian Journal of Clinical and Laboratory Investigation.
2013
No difference in portal and hepatic venous bacterial DNA in patients with cirrhosis undergoing transjugular intrahepatic portosystemic shunt insertion.
Liver International.
2013
Novel serological neo‐epitope markers of extracellular matrix proteins for the detection of portal hypertension.
Alimentary Pharmacology & Therapeutics.
2013
Soluble TNF-Alpha-Receptors I Are Prognostic Markers in TIPS-Treated Patients with Cirrhosis and Portal Hypertension.
PLoS ONE.
2013